Neutral
Sanofi's recent earnings report, while seemingly lackluster, may be influenced by conservative accounting practices. The company's statutory profit wa...
The FDA has granted Breakthrough Therapy designation to Sanofi's investigational oral drug venglustat for the treatment of neurological issues associa...
The U.S. FDA has approved Dupixent, co-developed by Regeneron and Sanofi, for the treatment of chronic spontaneous urticaria (CSU) in children aged 2 ...
Neutral
Sanofi is transitioning from blockbuster drugs to a focus on high-margin rare disease and immunology treatments, exemplified by its key product Dupixe...
Neutral
Assetmark Inc. lifted its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 24.2% in the 4th quarter, according to its most recent disclosure wi...